AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03182205 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IME
Description: The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
Study NCT02417870 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Study NCT01825590 — intervention group
Intervention type: OTHER
Intervention: Dialysate and serum sodium concentration aligned
Study NCT03041116 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosmetpantotenate
Description: Daily dosing
Study NCT03041116 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dosing
Study NCT00833248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
Study NCT00833248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
Study NCT00833248 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
Study NCT03393052 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary Angiography
Description: Comparison of left radial versus femoral access during coronary angiography of patients who have undergone coronary artery bypass grafting surgery
Study NCT02706392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02344628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Comparison of two different dosing strategies for the treatment of yaws
Study NCT02344628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of two different dosing strategies for the treatment of yaws
Study NCT03363048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restricted
Description: Certain foods and beverages are not allowed to be purchased with food benefit dollars.
Study NCT03363048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restriction plus Incentive
Description: Certain foods and beverages are not allowed to be purchased with food benefit dollars; 30% of the total dollars spent toward the purchase of certain foods result are added to their food benefit dollars.
Study NCT04397406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: The patients will receive 15 ml of 0.125% levobupivacaine.
Study NCT04397406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: The patients will receive 15 ml of 0.125% levobupivacaine.
Study NCT04397406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The patients will receive 13 ml of 0.125% levobupivacaine and 0.5μg/kg dexmedetomidine diluted in 2 ml saline.
Study NCT04397406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: The patients will receive 13 ml of 0.125% levobupivacaine and 25μg fentanyl diluted in 2 ml saline.
Study NCT02674581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral BMS-663068 (pro-drug)
Description: Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
Study NCT00332514 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: telephone call by a pharmacist
Study NCT00909142 — intervention group
Intervention type: DRUG
Intervention: Bonefos (Clodronate, BAY94-8393)
Description: Patients in regular clinical practice receiving Bonefos according to local drug information
Study NCT01619384 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week validated stress reduction program, designed to teach mindfulness.
Study NCT02805868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspiration and biopsy
Study NCT02805868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02805868 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV
Study NCT04009096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAd63 PvDBP and MVA PvDBP
Description: one dose of 5 x 10\^10 vp ChAd63 PvDBP and one dose of 2 x 10\^8 pfu MVA PvDBP 8 weeks later, in a heterologous prime-boost regimen.
Study NCT03747835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: Exposure and Response Prevention involves collaboratively developing a list of food-related fears with the patient and planning treatment sessions in which the patient is exposed to the fear and inhibits safety behaviors. The explicit goal of these exposure sessions will be to violate the patient's expectation regarding the feared stimulus, rather than to reduce fear.
Study NCT03747835 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational interviewing techniques including reflective listening to demonstrate empathy and understanding, asking questions to elicit change talk (speech that is pro-change), evaluating the decisional balance, and managing or rolling with resistance will be incorporated throughout the treatment sessions.
Study NCT02916498 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System
Description: Spinal cord stimulation for the management of chronic neuropathic pain
Study NCT02916498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System
Description: Spinal cord stimulation for the management of chronic neuropathic pain
Study NCT00107770 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sodium phenylbutyrate
Description: histone deacteylase inhibitor
Study NCT02293954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radionuclide imaging
Description: Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
Study NCT02706392 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ROR1 CAR-specific Autologous T-Lymphocytes
Description: Given IV
Study NCT00619866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elagolix
Description: Elagolix tablets administered orally
Study NCT00619866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo tablet administered orally
Study NCT01436227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01436227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib Hydrochloride
Description: Given PO
Study NCT01241123 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulation regimen
Description: Assistance and encouragement for at least ambulation 3 times a day
Study NCT01241123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitz-Markers
Description: radiopaque markers to subjectively follow the return of bowel function
Study NCT01241123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitz-Markers
Description: radiopaque markers to subjectively follow the return of bowel function
Study NCT01241123 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Daily abdominal x-rays
Description: daily abdominal x-rays for 7 days - to follow the radiopaque markers
Study NCT01241123 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Daily abdominal x-rays
Description: daily abdominal x-rays for 7 days - to follow the radiopaque markers
Study NCT02293954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET
Study NCT02293954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02293954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02293954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cu 64 anti-CEA monoclonal antibody M5A IV
Description: Cu 64 anti-CEA monoclonal antibody M5A IV
Study NCT01241123 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: pedometers
Description: to record the amount of ambulation
Study NCT01241123 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pedometers
Description: to record the amount of ambulation
Study NCT02221440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow nasal oxygen
Description: Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
Study NCT02221440 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Low flow room air
Description: Sham: oxygen will be administered by nasal catheter at a flow rate of 0 L/min.
Study NCT03627598 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: patients will receive high flow warmed air with low inspired fraction of oxygen between non invasive ventilation sessions
Study NCT03627598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard
Description: patients will receive low flow oxygen therapy at 1 to 4 liters per minute
Study NCT03858127 — intervention group
Intervention type: OTHER
Intervention: Collection of urine sample
Description: Collection of urine sample for measurement of LH and FSH
Study NCT03858127 — intervention group
Intervention type: OTHER
Intervention: Examination of genitalia
Description: Examination of genitalia
Study NCT03858127 — intervention group
Intervention type: OTHER
Intervention: Video messaging
Description: Short video of infant recorded at home by the parents
Study NCT02710032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network-Based Adherence Intervention
Description: Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
Study NCT02710032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Platform
Description: ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
Study NCT02302937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )
Description: laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
Study NCT02302937 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B will undergo laparoscopic TEP inguinal hernia repair with a single port
Description: Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
Study NCT04093154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearing the virtual headset
Description: watching the application by wearing virtual glasses to the child/adolescent
Study NCT01487434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check & Connect
Description: Structured mentoring and case management
Study NCT04002739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygraphy
Description: Patients will perform polygraphy during the CCU stay (baseline) and, if found to have a diagnosis of Obstructive Sleep Apnea (OSA) syndrome, will complete the study with a follow-up visit at 90-day (follow-up). Diagnosis of OSA syndrome will require an Apnea / Hypopnea Index (AHI) more than 5 events per hour.
Study NCT00260273 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behaviour Therapy
Description: therapy
Study NCT01461291 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iStent inject
Description: Implantation of two GTS400 stents using G2-M-IS iStent inject
Study NCT01461291 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Cataract surgery alone
Study NCT01192399 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study NCT03408431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu® AuraGain™
Description: Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
Study NCT03408431 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® AuraGain™
Description: Ambu® AuraGain™ laryngeal mask will be placed first, and then, a lubricated endotracheal tube will be gently intubated through the laryngeal mask under each position according to the assigned group.
Study NCT03408431 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck extension
Description: Patients' neck will be maximally extended (\~60°) during blind intubation.
Study NCT02997722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: IV infusion of ketamine 0.5 mg/kg administered over 45 minutes.
Study NCT02997722 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV infusion of 100 ml of normal saline over 45 minutes.
Study NCT03822273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture (TA)
Description: Procedure: real acupuncture.~Eight disposable, single use, sterilized, stainless steel needles are inserted at each session, and the bilateral LI4 (Hegu), SJ6 (Zhigou), ST36 (Zusanli) and GB34 (Yanglingquan) are used for acupuncture treatment. The acupuncture needles are to be inserted to a depth of 15-35 mm. All needles are rotated manually at least once at each session to elicit needle sensation (De qi). The needle retention time is 15 min.
Study NCT03822273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser acupuncture (LA)
Description: Procedure: laser acupuncture.~Participants allocated to the LA group receive laser acupuncture treatment at the same acupoints used in acupuncture group. The laser acupuncture therapy will be performed with the gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; and Bahr frequencies \[B1: 599.5 Hz, B2: 1199 Hz, B3: 2398 Hz, B4: 4776 Hz, B5: 9552 Hz, B6: 19,104 Hz, and B7: 38,208 Hz\]; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The laser will be applied to each point for 5 seconds, which delivered 0.375 J of energy at each of the acupoints: LI4 (Hegu, B3), SJ6 (Zhigou, B3), ST36 (Zusanli, B2) and GB34 (Yanglingquan, B2).
Study NCT03822273 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham laser acupuncture (SLA)
Description: Procedure: sham laser acupuncture.~Subjects in the control group receive sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in the LA group.
Study NCT02991352 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Image guided needle placement
Description: Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
Study NCT02785627 — intervention group
Intervention type: OTHER
Intervention: Comprehensive bone health assessment
Description: Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
Study NCT01011556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Teriparatide
Description: Administered subcutaneously once daily for 12 months
Study NCT02040909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
Study NCT02644070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alveolar bone preservation with mp3
Description: graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
Study NCT02644070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: alveolar bone preservation with apatos
Description: graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
Study NCT02644070 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilization with membrane
Description: socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
Study NCT02959346 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Procedure:~Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.~All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery.
Study NCT02959346 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Procedure:~Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.~The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).~Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery.
Study NCT00811850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Study NCT00811850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
Description: 1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
Study NCT03988205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient Care Model
Description: Outpatient care model includes a nurse teacher educational program, scheduled outpatient visit protocol, and quality of life surveys for both subjects and caregivers.
Study NCT03988205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is administered, according to FDA approval, to subjects who meet medical and logistical criteria for study enrollment.
Study NCT03085953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Veteran Supportive Supervisor Training
Description: The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period.